加拿大不列颠哥伦比亚省多发性硬化症的直接医疗费用:2001-2020年基于人群的队列研究
该研究利用加拿大不列颠哥伦比亚省2001至2020年基于人群的行政健康数据,将17,071例多发性硬化症(MS)患者与85,355名无MS对照按性别、年龄和队列进入日期匹配,计算直接医疗费用。结果显示MS每患者年超额费用为6,881加元(95%CI:6,713至7,049加元),其中药物费用占65%,使用疾病修正治疗(DMT)者超额费用更高。
要点
- MS每患者年超额直接医疗费用为6,881加元(95%CI:6,713至7,049加元)。
- 住院、门诊和药物费用分别占超额费用的25%、10%和65%。
- 频繁使用DMT者超额费用最高,达24,835加元(95%CI:24,528至25,141加元)。
核心结论
- MS的经济负担相当大,药物尤其是DMT是最大的费用驱动因素。
- 未来研究应探讨疾病管理策略(包括早期诊断和及时使用DMT)如何抵消未来和持续费用并改善患者生活质量。
研究设计与样本
- 回顾性匹配队列研究,使用2001至2020年基于人群的行政健康数据。
- 17,071例符合验证病例定义的MS患者与85,355名无MS对照按性别、年龄和队列进入日期匹配。
- 随访至2020年底或最后一次医疗资源使用,以先发生者为准。
- 计算包括门诊服务、住院和配发药物在内的直接医疗费用。
- 使用恒等链接和正态分布的广义线性模型估计MS超额费用,即MS患者与对照的平均费用差。
主要发现
- 总体72.4%为女性,队列进入时平均年龄为46.1岁。
- MS每患者年超额费用为6,881加元(95%CI:6,713至7,049加元)。
- 住院、门诊和药物费用分别占超额费用的25%、10%和65%。
- 至少有一次DMT处方的MS患者超额费用为13,267加元(95%CI:12,992至13,542加元),高于非DMT使用者3,469加元(95%CI:3,297至3,641加元)。
- 频繁DMT使用者的超额费用更高,为24,835加元(95%CI:24,528至25,141加元)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Multiple sclerosis (MS), a leading cause of nontraumatic neurologic disability in young adults, exerts a substantial economic burden on the health care system. The objective of this study was to quantify the excess health care costs of MS in British Columbia, Canada. METHODS: A retrospective-matched cohort study of patients with MS was conducted using population-based administrative health data from 2001 to 2020. Patients with MS who satisfied a validated case definition were matched to 5 unique controls without MS on sex, age, and cohort entry date. Patients and controls were followed to the end of 2020 or to their last health care resource use, whichever came first. We calculated the direct medical costs for each individual, including outpatient services use, hospital admissions, and dispensed medications. We used generalized linear models with an identity link and normal distribution to estimate the excess cost of MS as the mean cost difference between patients with MS and controls. All costs were reported in 2020 Canadian dollars. RESULTS: A total of 17,071 patients with MS were matched to 85,355 controls. Overall, 72.4% were female, and the mean age at cohort entry date was 46.1 years. The excess cost of MS was $6,881 (95% CI: $6,713, $7,049) per patient-year. Inpatient, outpatient, and medication costs accounted for 25%, 10%, and 65% of excess costs, respectively. Excess costs were higher in patients with MS with at least one disease-modifying therapy (DMT) prescription ($13,267; 95% CI: $12,992-$13,542) compared with non-DMT users ($3,469; 95% CI: $3,297-$3,641) and even higher among frequent DMT users ($24,835; 95% CI: $24,528-$25,141). Patients with MS with a history of at least one relapse requiring hospitalization had higher excess costs ($10,543; 95% CI: $10,136-$10,950) compared with patients with MS without a relapse; hospitalizations accounted for 51% of the costs in this group. The excess cost of hospitalizations was $1,391 lower among frequent DMT users than non-DMT users. DISCUSSION: The economic burden of MS is considerable, with medications, particularly DMTs, being the largest cost driver. Future studies should investigate how disease management strategies, including early diagnosis and timely use of DMTs, could offset future and ongoing costs while improving patients' quality of life.
引用
- Khakban A, Rodriguez Llorian E, Michaux KD, et al. Direct Health Care Costs Associated With Multiple Sclerosis: A Population-Based Cohort Study in British Columbia, Canada, 2001-2020. Neurology. 2022. PMID: 36450607. doi:10.1212/WNL.0000000000201645
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。